Oxidative Stress in Women Treated With Atosiban for Impending Preterm Birth

• Status: Completed
• Trial end date: 2018-12-30
• Target enrollment: 0
• Participant gender: Female

Summary

Oxidative stress is recognized as a important factor in the pathogenesis premature birth. Preterm birth is defined as delivery before 37 completed weeks of gestation and it is the leading cause of neonatal morbidity and mortality. The investigators conducted this analysis to investigate the safety of administration of Atosiban - a reversible, competitive antagonist of the oxytocin receptor in the treatment of preterm labor and its impact on the level of oxidative stress after 48 hours of tocolytic treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Polish Mother Memorial Hospital Research Institute
• Treatments: Atosiban; Vasotocin

Criteria

Inclusion Criteria:

• pregnant women between 24-35 weeks' gestation receiving prenatal care due to the risk of premature birth

• intact membranes

• evidence of premature labor (regular, painful and persistent uterine contractions; cervical changes)

Exclusion Criteria:

• acute fetal distress

• other conditions requiring immediate delivery (eclampsia and severe pre-eclampsia, placenta previa, abruptio placenta)

• vaginal bleeding,

• premature rupture of membranes

• chorioamnionitis,

• fetal congenital malformations,

• intrauterine growth restriction,

• the use of any tocolytic drugs during pregnancy before admission to the hospital

• circulatory system diseases (e.g. heart defects, hypertension),

• symptoms of infection

• other diseases that may increase oxidative stress